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Available online 20 June 2018Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), typiﬁed by the pulse-ﬁeld type
USA300, is an emerging endemic pathogen that is spreading rapidly among healthy people. CA-MRSA causes
skin and soft tissue infections, life-threatening necrotizing pneumonia and sepsis, and is remarkably resistant
to many antibiotics. Here we show that engineered liposomes composed of naturally occurring sphingomyelin
were able to sequester cytolytic toxins secreted by USA300 and prevent necrosis of human erythrocytes, periph-
eral blood mononuclear cells and bronchial epithelial cells. Mass spectrometric analysis revealed the capture by
liposomes of phenol-soluble modulins, α-hemolysin and other toxins. Sphingomyelin liposomes prevented he-
molysis induced by pure phenol-soluble modulin-α3, one of the main cytolytic components in the USA300
secretome. In contrast, sphingomyelin liposomes harboring a high cholesterol content (66 mol/%) were unable
to protect human cells from phenol-soluble modulin-α3-induced lysis, however these liposomes efﬁciently se-
questered the potent staphylococcal toxin α-hemolysin. In a murine cutaneous abscess model, a single dose of
either type of liposomeswas sufﬁcient to signiﬁcantly decrease tissue dermonecrosis. Our results provide further
insights into the promising potential of tailored liposomal therapy in the battle against infectious diseases.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Dermonecrosis1. Introduction
Community-associated methicillin-resistant Staphylococcus aureus
(CA-MRSA) is an emerging public health threat, especially the predom-
inant, most aggressive USA300 type [1]. Resistant tomany conventional
antibiotics, it rapidly spreads outside the health care setting and infects
even young, healthy individuals with no previous hospital exposure [2].
Infections caused by USA300 mainly manifest as purulent skin and soft
tissue infections (SSTIs) [1, 2] or life-threatening diseases such as necro-
tizing pneumonia and sepsis [1, 2]. CA-MRSA expresses an arsenal of cy-
totoxic virulence factors inﬂuencing the complex interplay between the
pathogen and the host's immune system [3–5].
Amajor virulence-associated feature of S. aureus is its capacity to kill
host cells, mediated by secreted toxins such as α-hemolysin,
leukocidins and phenol-soluble modulins (PSMs) [5]. α-Hemolysin
and PSMs have receptor-independent, cytolytic activities if present at
high levels [5, 6]. When expressed at lower concentrations, these toxinsall Research Station, V6T1Z4
).
. This is an open access article underexert additional pro-inﬂammatory and/or cytotoxic properties by bind-
ing to speciﬁc receptors [7–9].
For example,α-hemolysin, plays an important role during staphylo-
coccal pathogenesis, e.g. in SSTIs [10–12], mouse lung infection models
[13, 14], and sepsis [15]. It is secreted as soluble monomers, binds to
and activates the host cell receptor, A Disintegrin And Metalloprotease
10 (ADAM10) [9]. ADAM10 is present on human epithelial, endothelial
and myeloid cells but is absent on human erythrocytes [16]. Receptor
binding elicits powerful host inﬂammatory responses and the formation
of pore structures in the plasma membrane of host cells that ultimately
lead to the destruction of membrane integrity [16, 17].
PSMs are small (2–5 kDa), α-helical, amphipathic peptides
exhibiting multiple functions in Staphylococcus pathogenesis. α-Type
PSMs (PSM-α1, PSM-α2, PSM-α3, PSM-α4, δ-toxin) are ~20–30
amino acids and more cytolytic than the ~45 amino acid β-types
(PSM-β1, PSM-β2). PSM-α3 possesses the most potent killing activity
among all PSMs [6]. A receptor-independent mode of membrane inser-
tion enables PSMs to kill multiple eukaryotic cell types, including endo-
thelial, epithelial cells and myeloid cells (e.g., erythrocytes, monocytes,
and neutrophils) [4, 6]. PSMs also induce receptor-dependent host in-
ﬂammatory responses [8, 18, 19] and exhibit synergy with otherthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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leukocidin [PVL [11, 20]], boosting their pathogenic impact. Further-
more, PSMs are involved in bioﬁlm formation, a stress-induced bacterial
life-style that confers heightened adaptive antimicrobial resistance [4,
21]. The expression of the psmα and psmβ genes is strongly enhanced
at high bacterial cell densities [6, 22]. MRSA isolates from SSTIs, espe-
cially USA300, produce signiﬁcantly higher levels of PSMs than other
S. aureus stains [23].
Since the above-mentioned toxins harm host cells and contribute to
pathogenicity, sequestration and neutralization of one or more of these
virulence factors represents a promising therapeutic approach for atten-
uating disease severity. Recently, we reported that a liposomal-based
toxin-sequestration therapy protected host cells and attenuated bacte-
rial virulence in vitro and in vivo [24]. Engineered liposomes composed
of cholesterol and sphingomyelin (Ch:Sm, 66 mol/% cholesterol) efﬁ-
ciently scavenged a plethora of virulence factors, including
cholesterol-dependent cytolysins, phospholipase C and staphylococcal
α-hemolysin by mimicking plasma membrane lipid raft-like microdo-
mains that are the preferred target sites for many bacterial toxins [24,
25]. As a single therapy, Ch:Sm liposomes provided only partial protec-
tion against staphylococcal and pneumococcal supernatants in vitro and
in mouse infection models. However their combination with
sphingomyelin-only (Sm) liposomes was fully protective, indicating
that Sm liposomes neutralized as-yet unidentiﬁed virulence factors dis-
tinct from those neutralized by Ch:Sm liposomes [24]. The mixture of
both liposome types under the trade name CAL02 is currently being
tested in a clinical trial against severe pneumococcal pneumonia
(ClinicalTrials.gov Identiﬁer: NCT02583373).
Here we demonstrate that Sm, but not Ch:Sm liposomes bound and
neutralized hemolytic virulence factors present in USA300 supernatants
and protected human red blood cells (RBCs), peripheral bloodmononu-
clear cells (PBMCs) and bronchial epithelial 16HBE140- (HBE) cells
from rapid cell lysis. Mass spectrometric analysis of bacterial proteins
bound by the Sm liposomes revealedα-type PSMs as an interacting tar-
get. Sm liposomes, but not Ch:Sm liposomes decreased hemolysis in-
duced by puriﬁed recombinant PSM-α3. In contrast to Sm liposomes,
Ch:Sm liposomes efﬁciently bound α-hemolysin. Furthermore, both
types of liposomes attenuated CA-MRSA virulence by signiﬁcantly re-
ducing dermonecrosis in a murine cutaneous abscess model.
2. Materials and Methods
2.1. Liposomes
Unilamellar cholesterol:sphingomyelin (Ch:Sm, 66 mol/% choles-
terol, 40 mg/ml, diameter 130 nm) and sphingomyelin (Sm,
40 mg/ml, diameter 60 nm) liposomes in sodium Tyrode's buffer
(140 mMNaCl, 5 mM KCl, 1 mMMgCl2, 2.5 mM CaCl2, 10 mM glucose,
10 mM HEPES; pH = 7.4) were provided by Lascco (Geneva,
Switzerland, product name CAL02).
2.2. Bacterial strains and supernatants
The MRSA USA300 pulse ﬁeld type isolate LAC (USA300) was kindly
provided by Michael Otto (National Institute of Health, Bethesda, MD)
and bioluminescent LAC USA300 was kindly provided by Scott Stibitz
(Food and Drug Administration, Silver Spring, MD). Bacteria were cul-
tured in Tryptic Soy Broth (TSB, Becton Dickinson). Overnight cultures
were diluted in fresh TSB to an optical density OD600 of 0.1 and incu-
bated at 37 °C under shaking conditions for 22 h. Bacteria were pelleted
(5000 ×g, 10 min) and the resulting supernatants were ﬁlter sterilized
(pore size 0.2 μm, Nalgene).
If indicated, bacterial supernatants were high-speed centrifuged
(100,000 ×g) at 4 °C for 1 h. The resulting supernatants were treated
with liposomes or sodium Tyrode's buffer (vehicle) for 5 min. Subse-
quently, liposomes were pelleted (100,000 ×g) at 4 °C for 1 h. Theresulting liposome-free supernatants were used for the cytotoxicity
assay in Fig. 1e. The liposome/toxin or vehicle/toxin pelletswere applied
to SDS-PAGE or mass spectrometric analysis.2.3. Human cells
Peripheral blood mononuclear cells (PBMCs) and red blood cells
(RBCs) were isolated from the blood of healthy, consenting human vol-
unteers (following the University of British Columbia ethics guidelines).
Blood was collected in sodium heparin anticoagulant collection tubes
(BD Biosciences), diluted in phosphate buffered saline (PBS,
ThermoFisher/Gibco) and layered onto Lymphoprep density gradient
medium (STEMCELL Technologies). After centrifugation (500 ×g for
20 min) the buffy coat was transferred to a new tube, washed three
times with PBS and resuspended in RPMI-1640 Medium (+25 mM
HEPES, +L-Glutamine, GE Healthcare) supplementedwith 10% fetal bo-
vine serum (FBS, ThermoFisher/Gibco). PBMCs were seeded at density
of 100,000 cells and rested.
RBCs were collected from the bottom of the density gradient,
washed three times with PBS and stored for a maximum of 4 weeks in
Alsever's solution (Sigma Aldrich).
The human bronchial epithelial cell line 16HBE14o- (HBE, RRID:
CVCL_0112) was kindly provided by Dr. D. Gruenert (University of Cal-
ifornia San Francisco). HBE cells were maintained in MEM medium
(ThermoFisher/Gibco) supplemented with 10% FBS, 2 mM L-glutamine
(ThermoFisher/Gibco) and 1% penicillin/streptomycin (ThermoFisher/
Gibco) at 37 °C in 5% CO2. Cells were dissociated with 0.25% trypsin-
EDTA (ThermoFisher/Gibco) at 80–90% conﬂuency.2.4. Hemolysis assay
Prior to use, RBCs were washed three times with TSB (1000 × g,
10 min). Serial dilutions of liposomes were incubated with bacterial su-
pernatants (50 μl) and 2% RBCs in a 200 μl reaction volume with TSB in
microtiter plates (Falcon). The hemolytic activity of puriﬁed staphylo-
coccal PSM-α3 peptide (IBT Bioservices, Cat# 1401–004) was assessed
in PBS. Triton X-100 (2% v/v, Sigma–Aldrich)-treated RBCs served as a
positive control and TSB-treated RBCs as a negative control. After incu-
bation for 1 h at 37 °C, RBCs were pelleted (1000 × g, 10 min) and the
hemoglobin content in the supernatant was measured at OD450 (refer-
ence 630 nm) using amicroplate reader. Relative hemolysis (%)was cal-
culated as (ΔODsample − ΔODnegative control)/(ΔODpositive control −
ΔODnegative control) × 100.2.5. Cytotoxicity assays
Cytotoxicity assays were performed in cell-culture treated micro-
titer plates (Costar). 100,000 PBMCs were seeded directly after their
isolation in RPMI +10% FBS (100 μl) and rested for 1 h. 40,000 HBE
cells were seeded two days prior treatment in MEM + 10% FBS and
grown to conﬂuency. Shortly before treatment the medium was re-
placed with MEM + 1% FBS (100 μl). Bacterial supernatants (12.5 μl
PBMCs, 50 μl HBE cells) and liposomes (300 μg/ml) or sodium
Tyrode's buffer (vehicle) were added (total reaction volumes: 150
μl PBMCs, 200 μl HBE cells). Triton X-100 (2% v/v, Sigma–Aldrich)-
treated PBMCs or HBE cells served as a positive control and TSB-
treated PBMCs or HBE cells as a negative control. After incubation
for 1 h at 37 °C, PBMCs or HBE cells were centrifuged (500 ×g,
5 min) and the lactate dehydrogenase (LDH) content in the superna-
tant was assessed with the Cytotoxicity Detection KitPlus (Roche) ac-
cording to the manufacturer's instructions. Relative LDH release (%)
was calculated by (ΔODsample − ΔODnegative control)/(ΔODpositive con-
trol − ΔODnegative control) × 100.
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Conﬂuent HBE cells in cell-culture treated glass bottom microtiter
plates (Greiner bio-one) were stained with the CellTracker Orange
CMTMR dye (5 μM, excitation 548/emission 576, ThermoFisher Scien-
tiﬁc, Cat# C2927) in serum-free MEM for 30 min. The medium was re-
placed with 100 μl MEM without phenol red (ThermoFisher/Gibco)
and cells were treated with USA300 supernatants and liposomes (300
μg/ml) or sodium Tyrode's buffer (vehicle) for 1 h. Imaging was per-
formedwith a ZEISS LSM 800 confocal microscope equippedwith an in-
cubation system at 37 °C and analyzed with the ZEISS ZEN software 2.3
blue edition.
2.7. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and silver staining
Sampleswere resuspended in 2 × SDS-loading buffer (65.8mMTris-
HCL pH= 6.8, 26.3% (w/v) glycerol, 2.1% SDS, 0.01% bromophenol blue,
355mM2-mercaptoethanol) andwere boiled at 95 °C for 5min. Pellets,
bacterial supernatants and a protein standard (Precision Plus Protein
Dual Colour Standard, Bio-rad) were applied to SDS-polyacrylamide
gels (12% Mini-PROTEAN TGX stain-free precast gels, Bio-rad) and ran
in SDS-running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) at
150 V for ~30 min. Protein silver staining was performed as described
[26]. In brief, the gel was soaked in 50% methanol overnight, washed
in deionized water and agitated for 10 min in staining reagent (1.4 ml
ammonium hydroxide, 21.0 ml of 0.36% NaOH, 4.0 ml of 20% w/v
AgNO3, increased to 100 ml with deionized water). After washing the
gel in deionized water, it was incubated in developer solution (2.5 ml
citric acid (1% w/v), 0.25 ml formaldehyde (38% v/v), increased to
250 ml with deionized water). When the gel achieved the desired
state of staining, it was soaked in 50% methanol/10% acetic acid. Bands
were visualizedwith an imaging system (ChemiDoc Touch Imaging Sys-
tem, Bio-rad).
2.8. Western blotting
All stepswere performed at room temperature. SDS-gelswere trans-
ferred to a PVDF membrane (Immun-Blot PVDF membrane, Bio-rad) in
Towbin buffer (25mM TRIS, 192mMGlycine, 20%methanol, pH= 8.6)
at 30 V overnight. The membrane was blocked in blocking buffer (PBS,
0.3% Tween-20, 3% bovine serum albumin) for 1 h and incubated with
1 μg/ml of a monoclonal mouse anti-alpha-hemolysin antibody (8B7
N-terminal, ab190467, Abcam) diluted in washing buffer (PBS, 0.3%
Tween-20, 1% bovine serum albumin) for 2 h. After washing the mem-
brane three times for 5 min with washing buffer, it was incubated
with an ECL mouse IgG, HRP-linked whole antibody from sheep
(NXA931, Amersham, RRID:AB_772209) at a dilution of 1 to 5000 in
washing buffer for 1 h. The membrane was washed three times with
washing buffer and the Clarity Western ECL detection Kit (Bio-rad)
was used according to the manufacturer's instructions. Bands were vi-
sualized with an imaging system. Black and white values were inverted
for data presentation.
2.9. Mass spectrometry
In gel digestion and mass spectrometric analysis of Sm liposome/
toxin pellets (35 μl/sample)were performed by the Proteomics Core Fa-
cility of the University of British Columbia (Vancouver, BC, Canada). The
in gel digestion procedure was performed as described by Shevchenko
et al. (1996) [27]. In brief, the protein lanes were excised from SDS-
PAGE, chopped into small pieces, washed with 50% digestion buffer
(50 mM NH4HCO3) and 50% EtOH, dehydrated with absolute EtOH.
Gel pieces were incubated with dithiothreitol (10 mM) at 56 °C for
45 min and with iodoacetamide (55 mM) for 30 min at room tempera-
ture. After washing with digestion buffer, gel pieces were dehydratedand remaining EtOH was removed by vacuum centrifugation. Samples
were incubated in trypsin solution (12.5 ng/μL) at 37 °C overnight.
Neat acetic acid was added, samples were vortexed and the liquid was
collected. Three gel extractions were performed with the following ex-
traction solutions: [1] 0.5% AcOH, [2] 30% MeCN, 0.5% AcOH, and [3]
100%MeCN. All liquids were combined and the organic portion was re-
moved by vacuum centrifugation. Following digestion, the samples
were desalted on C18 STAGE tips [28] eluted with 80% acetonitrile,
dried and suspended in 3% acetonitrile +0.1% formic acid. Approxi-
mately 5 μg of proteinwas loaded onto anAgilent 6550QToFmass spec-
trometer, through and Agilent 1200 capillary HPLC connected by a
2.1 mm × 250 mm POROShell C18 column. The QToF was run in
AutoMS/MS mode, at 2 spectra/s for MS and 3 spectra/s for MS/MS
scans. LC-MS/MS datawas processed usingMaxQuant 1.5.3.30 using de-
fault values for Agilent QToF data (including 1% FDR), against the
Uniprot Staphylococcus aureus USA300 (UP000001939) database.
2.10. Murine cutaneous infection model
The mouse skin infection model was performed as described previ-
ously [29]. In brief, the backs of 6-week old female CD-1 mice (Charles
River Laboratories, Wilmington, MA) were shaved and depilated.
USA300 and bioluminescent USA300 were grown to OD600 of 1 in TSB,
washed twice with PBS and resuspended to a ﬁnal concentration of 5
× 107 colony forming units (CFU)/50 μl. Bacteria (50 μl) were injected
subcutaneously to the right ﬂank of the back. Sm or Ch:Sm liposomes
(50 μl of 40mg/ml, ~80mg/kg) were applied via intra-abscess injection
after 1 h. After 72 h dermonecrosis was measured using a caliper and
skin abscesses were excised and homogenized for CFU quantiﬁcation
(non-luminescent USA300). Bioluminescent USA300 LAC bacteria
were used to track the disease progress (abscess size and bacterial bur-
den) in real-time. Mice were anesthetized with isoﬂurane and imaged
using the Lumina in vivo Imaging System (IVIS) (Perkin Elmer,Waltham
MA) up to 10 days post-infection. Luminescence counts were deter-
mined using Living Image® Software, and reported as region of interest
(ROI) values. Abscess sizemeasurements were read up to 10 days using
a caliper. All animal experiments were performed in accordance with
The Canadian Council on Animal Care (CCAC) guidelines and were ap-
proved by the University of British Columbia Animal Care Committee.
2.11. Quantiﬁcation and statistical analysis
Statistical signiﬁcancewas analyzed byGraph PadPrism7. All details
(statistical test, number of experiments, and deﬁnition of signiﬁcance)
are provided in the corresponding ﬁgure legends.
3. Results
3.1. Sphingomyelin liposomes protected human cells from necrosis induced
by the S. aureus USA300 secretome
Initially we tested the efﬁcacy of Sm and Ch:Sm liposomes in
preventing lysis of human red blood cells (RBCs) induced by superna-
tants of USA300 grown for 22 h. Hemolysis, as measured by the leakage
of hemoglobin from ruptured erythrocytes, was reduced by N90% if Sm
liposomes were added at concentrations of ≥300 μg/ml (Fig. 1a). Inter-
estingly, the Ch:Sm liposomes did not decrease hemolysis at the highest
concentration tested (600 μg/ml) although the same concentration of
the sphingomyelin lipid in Sm liposomes (200 μg/ml) led to a reduction
of N80%. Addition of Sm, but not Ch:Sm liposomes (both at 300 μg/ml),
signiﬁcantly diminished necrosis, induced by USA300 supernatants, of
human peripheral blood mononuclear cells (PBMCs) (Fig. 1b) and HBE
cells (Fig. 1c). Laser scanning micrographs of HBE cells stained with
CellTracker Orange, a cell-permeable dye that is intracellularly con-
verted to ﬂuorescent membrane-impermeant products, illustrated the
destructive effect of USA300 supernatants leading to disassembly of
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nal (Fig. 1d). Addition of Ch:Sm liposomes slightly attenuated cell frag-
mentation,whereas Sm liposomes prevented fatal necrosis, as indicated
by the retention of the cell shape and intracellular ﬂuorescent products
(Fig. 1d). We further addressed whether cytolytic virulence factors be-
came liposome-bound and thus might be removed with the liposomes.
Virulence factors in bacterial supernatants were neutralized by liposo-
mal treatment and the liposomes were subsequently removed by cen-
trifugation. This revealed that the cell cytolytic factors in the
supernatants were sequestered by Sm, but not by Ch:Sm liposomes
(Fig. 1e).
3.2. Sphingomyelin liposomes neutralized α-type phenol-soluble modulins;
cholesterol-containing liposomes bound α-hemolysin
To identify secreted bacterial virulence factors that were bound to
the liposome pellets, proteins were separated by SDS-PAGE (Fig. 2a).
Protein bands in the liposome-free control (p. vehicle) indicated the
presence of a considerable non-speciﬁc protein background. However,
a prominent band appeared in the Ch:Sm liposome pellet at ~35 kDa
(Fig. 2a, lane p; Ch:Sm, band marked with an arrow). Immunoblotting
with an anti-α-hemolysin antibody conﬁrmed the identity of this
band demonstrating that Ch:Sm liposomes efﬁciently sequestered α-
hemolysin (36 kDa) from USA300 supernatants, while Sm liposomesFig. 1. Liposomal treatment decreased necrosis of human cells induced by the secretome o
concentrations of sphingomyelin (Sm) and cholesterol:sphingomyelin (Ch:Sm) liposomes
donors). (b-d) Human cells were incubated with sodium Tyrode's buffer (vehicle), bacterial s
e) The release of lactate dehydrogenase (LDH) of challenged human cells was determined. (
condition (one-way ANOVA Dunn's multiple comparisons test, ∗∗∗∗p b .0001, ns = not sign
bacterial ﬁltrates per condition (one-way ANOVA Dunn's multiple comparisons test, ∗∗∗∗p b
CellTracker Orange. HBE cells were treated with sodium Tyrode's buffer (vehicle), bacterial su
Ch:Sm liposomes (supernat+Ch:Sm) (representative images from 3 bacterial ﬁltrates per con
Sm liposomes (300 and 600 μg/ml), or vehicle and subsequently depleted of liposomes, were
per condition, one-way ANOVA Dunn's multiple comparisons test, ∗∗∗∗p b .0001, ∗∗∗p b .001, nsequestered lower amounts and the vehicle pellet showed no signal
(Fig. 2b; see Supplementary Fig. 1 for the complete Western Blot).
Mass spectrometric analysis of the Sm pellet was performed to verify
the presence of virulence factors and led to the identiﬁcation of 159pro-
teins (Supplementary Table 1) commonly found in 3 independent bac-
terial supernatant preparations. As expected, proteomic analysis of the
Sm/protein pellets reﬂected most of the proteins secreted by USA300.
In addition to α-hemolysin (Hla), the bi-component leukocidin PVL
(LukS-PV, LukF-PV), γ-hemolysin components A (HlgA) and B (HlgB),
PSM-α1, 3, and 4, and δ-hemolysin (Hld) were also present in the Sm/
protein pellets (Table 1). Since PSMs, especially PSM-α3, are the main
cytolytic components of USA300 supernatants [6], and can interact
with PC liposomes [30, 31], we tested whether engineered liposomes
sequestered puriﬁed PSM-α3. PSM-α3 (50 μg/ml) led to 60% hemolysis
of human RBCs. Sm but not Ch:Sm liposomes (300 μg/ml) signiﬁcantly
diminished PSM-α3-induced hemolysis (Fig. 2c).
3.3. Liposomes reduced dermonecrosis in a murine USA300 abscess model
Since USA300 skin infection studies in rodents have demonstrated
the importance of α-type PSM toxins [6, 12] and α-hemolysin [11, 32]
in tissue necrosis, we investigated whether Sm and Ch:Sm liposomes
could be used therapeutically to target α-type PSMs and α-hemolysin
of USA300 in a murine cutaneous abscess model.f S. aureus USA300. (a) Human red blood cells (RBCs) were incubated with increasing
(≥3 bacterial ﬁltrates were tested per condition, RBCs were isolated from ≥3 different
upernatants and Sm or Ch:Sm liposomes (both 300 μg/ml, or as indicated) for 1 h. (b, c,
b) PBMCs were isolated from 5 different donors and 6 bacterial ﬁltrates were tested per
iﬁcant). (c) Human bronchial epithelial 16HBE14o- cells (HBE) were incubated with 6
.0001, ns = not signiﬁcant). (d) Laser scanning micrographs of HBE cells stained with
pernatant (supernat), supernat and Sm liposomes (supernat+Sm), and supernatant with
dition). Scale bar = 50 μm. (e) USA300 supernatants (50 μl) pre-incubated with Sm, Ch:
applied to human bronchial epithelial HBE cells for 1 h (≥3 bacterial ﬁltrates were tested
s = not signiﬁcant). Error bars (a-c, e), mean ± s.e.m.
Fig. 2. Liposomes neutralizedmajor S. aureusUSA300 virulence factors and attenuated dermonecrosis in amurine cutaneous abscessmodel. (a) Sodiumdodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) of the USA300 supernatant (supernat) and pellets (p.) of vehicle, sphingomyelin (Sm) and cholesterol:sphingomyelin (Ch:Sm) liposome-treated supernatant
revealed a strong protein band in p. Ch:Sm (25–37 kDa) indicated by an arrow (representative data of ≥3 bacterial supernatants per condition). (b) Western blotting with an anti-α-
hemolysin antibody (anti-Hla antibody) identiﬁed the ~35 kDa protein band of p. Ch:Sm (arrow) as α-hemolysin (representative data of ≥2 bacterial supernatants per condition).
(c) Human red blood cells were treated with puriﬁed phenol-soluble modulin α3 (PSM-α3, 50 μg/ml) and Tyrode's buffer (vehicle), Sm or by Ch:Sm liposomes (both liposomes 300
μg/ml) (n ≥ 3, two independent experiments, ∗p b .05). Error bars, mean ± s.e.m. (d-e) Sm or Ch:Sm liposomes (80 mg/kg) or vehicle were applied 1 h after the injection of 5 × 107
CFU/injection USA300 in the back of CD-1 mice (vehicle and Sm treatment: n ≥ 9, four independent experiments; Ch:Sm treatment n = 8, two independent experiments, box and
whiskers plot). (d) Dermonecrosis (Kruskal-Wallis and Dunn's multiple comparisons test, ∗∗p b .01, ∗p b .05, ns = not signiﬁcant) and (e) CFU/abscess were evaluated 72 h after
infection. (f-g) Sm or Ch:Sm liposomes (80 mg/kg) or vehicle were applied 1 h after the injection of 5 × 107 CFU/injection bioluminescent USA300 in the back of CD-1 mice and the
disease progress was monitored up to 10 days post-infection (one experiment, number of mice in brackets, error bars, mean ± s.e.m.). (f) Abscess size measurements (two-way
ANOVA, Dunnett's multiple comparisons test, compared to vehicle, ∗∗∗∗p b .0001, ∗∗∗p b 0.001, ∗∗p b .01, ∗p b .05). (g) Bacterial loads indicated by luminescence counts.
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induce dermonecrosis, redness or any other sign of inﬂammation. In-
triguingly, a single dose of Sm or Ch:Sm liposomes (80 mg/kg) applied
subcutaneously 1 h after infection signiﬁcantly decreased USA300-
induced tissue necrosis measured 72 h post infection (Fig. 2d). Liposo-
mal treatment did not reduce the bacterial load (Fig. 2e). Abscess sizes
and bacterial burden measurements of abscesses induced by biolumi-
nescent USA300 up to 10 days post-infection and are shown in Fig. 2f
and g, respectively. These results showed that Sm liposomes caused
moderate but signiﬁcant decreases at days 1 and 2, while a single doseof Ch:Sm liposomes caused very substantial to complete abrogation of
tissue necrosis at all measured time points up to day 10. In contrast
there was no signiﬁcant change in bioburden on any day, but rather a
steady decline in concentrations over the 10-day experiment.
4. Discussion
PSMs and α-hemolysin are critical determinants of CA-MRSA viru-
lence [4, 6, 12, 16, 19, 20, 23]. Studies investigating the effect of PSMs
in animal models of SSTIs have shown that dermonecrosis caused by a
Table 1
Selection of virulence-associated S. aureus USA300 proteins found in the sphingomyelin liposome/toxin pellets identiﬁed by mass spectrometry.
Protein Gene Name
Locus Tag
Size
(kDa)
Human host cell targets
α-hemolysin hla
SAUSA300_1058
36 Cholesterol and sphingomyelin enriched microdomains [24]; A Disintegrin And Metalloprotease 10
(ADAM10) [9]
γ-hemolysin component A hlgA
SAUSA300_2365
35 Chemokine receptors [40, 41]
γ-hemolysin component B hlgB
SAUSA300_2367
37 Chemokine receptors [40, 41]
Panton-Valentine leukocidin, LukS-PV lukS-PV
SAUSA300_1382
35 Complement receptors [41, 42]
Panton-Valentine leukocidin, LukF-PV lukF-PV
SAUSA300_1381
37 Complement receptors [41, 42]
δ-hemolysin hld
SAUSA300_1988
5 Receptor-independent binding to the plasma membrane [6]; formyl peptide receptor 2 (FPR2/ALX) [8]
Phenol-soluble modulin α1 peptide,
PSM-α1
psmA1
SAUSA300_0424.4
2 Receptor-independent binding to the plasma membrane [6]; formyl peptide receptor 2 (FPR2/ALX) [8]
Phenol-soluble modulin α3 peptide,
PSM-α3
psmA3
SAUSA300_0424.2
3 Receptor-independent binding to the plasma membrane [6]; formyl peptide receptor 2 (FPR2/ALX) [8]
Phenol-soluble modulin α4 peptide,
PSM-α4
psmA4
SAUSA300_0424.1
2 Receptor-independent binding to the plasma membrane [6]; formyl peptide receptor 2 (FPR2/ALX) [8]
The full list of proteins commonly found in three bacterial supernatant preparations is given in Supplementary Table 1.
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whereas the deletion of β-type PSMs had no effect and the knockout of
δ-toxin showed only a modest reduction of virulence [4, 6, 12]. During
SSTIs, PSMs cause the massive recruitment of neutrophils and contrib-
ute to tissue damage [6, 18, 20]. Furthermore, PSMs have been shown
to inﬂuence the expression of virulence-promoting α-hemolysin [11],
a toxin that is also involved in abscess formation [11, 32].
Here, we demonstrated that PSM-α3 was bound and neutralized by
Sm liposomes in vitro (Fig. 2c) and that dermonecrosis was attenuated
by Sm liposome treatment in a cutaneous abscess mouse model
(Fig. 2d, f). Therefore we suggest that Sm liposomes sequester α-type
PSMs and protect host cells from deleterious PSM effects.
Surewaard et al. (2012) showed that the lytic and pro-inﬂammatory
activities of PSMswere blocked in a serum environment. They identiﬁed
lipoproteins as PSM scavengers and reasoned that PSMs preferentially
bound the lipid rather than protein components. Thus PSM-α1, PSM-
α2, PSM-α3, PSM-α4 and δ-toxin were efﬁciently sequestered by high
density lipoprotein (HDL) isolated from S. aureus MW2 human blood
cultures. They concluded that PSMsmainly contributed to pathogenesis
by acting intracellularly after bacterial uptake by neutrophils rather
than as secreted toxins [33]. To our knowledge, no data regarding
in vivo PSM concentrations during skin infection or other USA300 ani-
mal models exist. However in SSTIs it is likely that localized bacterial
densities and consequent quorum sensing result in sufﬁciently high
local PSM concentrations to promote receptor-dependent pro-
inﬂammatory responses [8, 18, 19], the potentiation of other virulence
factors [11, 20] and liberation of bacterial cytoplasmic protein stores in-
cluding other toxins [22, 34].
In contrast to Sm liposomes, Ch:Sm liposomes efﬁciently seques-
tered α-hemolysin [24] (Fig. 2b) but did not target PSM-α3 (Fig. 2c)
or other factors responsible for prompt host cell lysis (Fig. 1). Previous
studies demonstrated that adding ≥50mol/% cholesterol concentrations
into dipalmitoyl-phosphatidylcholine (DPPC) liposomes led to in-
creased membrane rigidity and negatively affected but did not
completely block the vesicle-lysing activity of PSMs [31]. This may ex-
plain the poor efﬁcacy of the 66 mol/% cholesterol-containing Ch:Sm li-
posomes in protecting host cells from PSM-mediated lysis. However,
Ch:Sm liposomes were very effective in reducing tissue necrosis in the
murine abscess model (Fig. 2d, f).
We point out that the high efﬁcacy of Sm liposomes in neutralizing
PSM-α3 and Ch:Sm liposomes in sequestering α-hemolysin in vitro
does not exclude the possibility of binding of other staphylococcal or
host proteins to the liposomes during the infection. Moreover, the factthat liposomes do not exclusively bind one toxin type (Supplementary
Table 1) confers on them even greater therapeutic power due to broad
spectrum protection of host cells.
Blocking PSMs or α-hemolysin in vivo is a desired strategy to atten-
uate overall virulence. To date several approaches exist affecting staph-
ylococcal PSM expression (8, 29, 35). Recently we demonstrated that
the cationic synthetic peptide DJK-5 targeted the bacterial stringent
stress response in theUSA300murine cutaneous abscessmodel, leading
to a signiﬁcant reduction of the lesion size as well as the bacterial bur-
den. In vitro, the expression of stringently regulated PSMs was sup-
pressed at sub-lytic DJK-5 concentrations [29]. This constitutes an
indirect approach to target PSM expression. Other studies investigated
the potential of blocking bacterial PSM export systems [35] or the
human formyl peptide receptor 2 (FPR2/ALX) that senses PSMs and
controls PSM-induced inﬂammatory processes [8]. Although monoclo-
nal antibodies against α-hemolysin have been shown to be protective
in a CA-MRSA lung infection model [36], to date no PSM antibodies
have been developed, probably because of the high amino acid se-
quence diversity and overlapping functions of PSMs [37].
In contrast to therapeutic strategies interveningwith the expression
of staphylococcal virulence-associated genes, we demonstrated here a
liposome-based strategy to sequester the most potent S. aureus toxins.
The neutralization of α-type PSMs by Sm liposomes and α-hemolysin
by Ch:Sm liposomes could beneﬁcially inﬂuence the course of disease
during localized infections such as necrotizing pneumonia or SSTIs. Li-
posomal therapy is not strain speciﬁc and exerts no known selective
pressure on pathogens. To date, incision and drainage followed, in se-
vere cases, by antibiotic therapy are the recommended treatment for
cutaneous abscesses [38]. Nevertheless, in killing bacteria, antibiotic
treatment can cause massive liberation of host cell-damaging and pro-
inﬂammatory bacterial agents [39]. In contrast, the neutralization of
virulence-promoting factors disarms bacteria, prevents tissue damage
and supports the immune system [24]. The targeting and neutralization
of PSMs and α-hemolysin by liposomes may be a valuable supportive
therapy for the treatment of SSTIs. After incision and drainage of ab-
scesses, liposomes added to topical creams or adjunctive to antibiotics
may have toxin sequestration and health-promoting effects.Conﬂict of Interest
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